Skip to main content
Addgene

pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA
(Plasmid #86986)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 86986 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    Bluescript
  • Backbone size w/o insert (bp) 2770
  • Total vector size (bp) 10146
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    Cas9-venus
  • Species
    Synthetic; Streptococcus pyogenes
  • Insert Size (bp)
    4938
  • Promoter CAG
  • Tag / Fusion Protein
    • Cas9-Venus fusion protein (C terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site PacI (not destroyed)
  • 3′ cloning site MluI (not destroyed)
  • 5′ sequencing primer M13 reverse
  • 3′ sequencing primer M13 forward
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA was a gift from Ralf Kuehn (Addgene plasmid # 86986 ; http://n2t.net/addgene:86986 ; RRID:Addgene_86986)
  • For your References section:

    Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9. Yumlu S, Bashir S, Stumm J, Kuhn R. Methods Mol Biol. 2019;1961:137-151. doi: 10.1007/978-1-4939-9170-9_10. 10.1007/978-1-4939-9170-9_10 PubMed 30912045